



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Oxytocin

Non-proprietary name

Oxytocin

Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection regarding shock of the Adverse reaction section, the following text should be revised (underlined parts are revised):

Shock and anaphylaxis:

Shock and anaphylaxis may occur. Patients should be carefully monitored. If abnormalities such as decreased blood pressure, rash, redness, itching, angioedema, dyspnea, and cyanosis are observed, administration of this drug should be discontinued and appropriate measures should be adopted.

Note

Oxytocin is designated as a drug requiring preparation of a Drug Guide for Patients.